Swiss drugmaker Roche is digging in for a long fight after gene sequencing company Illumina rejected its $5.7 billion hostile takeover bid as inadequate and said it would be more successful on its own.
Roche digs in for long fight for Illumina
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.